Partnership Forms for Development of Inhalable Formulation to Treat Lung Cancer, Lung Fibrosis, and SARS-CoV-2

Signal Rx Pharmaceuticals, Crystec, and ADYA Consulting are collaborating on the development of an inhaled dry powder formulation of SF2523 to treat pulmonary fibrosis, lung cancer, and SARS-CoV-2 related illnesses.